This article was originally published Dec. 30.

Building on last year's trend of numerous mergers and acquisitions within the next-generation sequencing market, in 2013, the space was again marked more by business deals and less by sequencing technology breakthroughs.

Sequencing companies sought to gain an edge over the competition through license agreements, mergers, and acquisitions — particularly those that focused on clinical applications — while companies outside of the next-gen space sought to get in on the sequencing game.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.